Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes
Brief Summary: This trial is conducted in North America (the United States of America (USA) and Mexico).

The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind trial period plus a 52-week open-label extension (week 104) followed by an additional 156-week continued open-label extension. The total duration of the treatment period is planned to be 260 weeks (5 years).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Exenatide Once Weekly | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine | Intervention Type: DRUG; Name: Exenatide Once Weekly; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): 2
B: Arm Label: Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: metformin | Arm Label: Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg; Type: EXPERIMENTAL; Interventions: Drug: metformin, Drug: liraglutide | Arm Label: Sita -> Sita; Type: ACTIVE_COMPARATOR; Interventions: Drug: sitagliptin, Drug: metformin | Arm Label: Sita -> Sita -> Lira 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: sitagliptin, Drug: metformin | Arm Label: Sita -> Sita -> Lira 1.8 mg; Type: EXPERIMENTAL; Interventions: Drug: sitagliptin, Drug: metformin, Drug: liraglutide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg, Sita -> Sita -> Lira 1.2 mg | Intervention Type: DRUG; Name: sitagliptin; Assigned to Arm(s): Sita -> Sita, Sita -> Sita -> Lira 1.2 mg, Sita -> Sita -> Lira 1.8 mg | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg, Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg, Sita -> Sita, Sita -> Sita -> Lira 1.2 mg, Sita -> Sita -> Lira 1.8 mg | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg, Sita -> Sita -> Lira 1.8 mg
C: Arm Label: Lira 1.8; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Lira 1.2; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Glimepiride - 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: placebo | Arm Label: Glimepiride - 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Glimepiride - 1, Glimepiride - 2 | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 1.2, Lira 1.8 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glimepiride - 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glimepiride - 2
D: Intervention Type: DRUG; Name: Albiglutide (GSK716155) or exenatide; Assigned to Arm(s): N/A

Answer: C